Stay updated on TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin
Sign up to get notified when there's something new on the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page.

Latest updates to the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page
- Check4 days agoChange DetectedLast update posted date updated to 2025-02-24 with minor textual edits; no changes to study design, eligibility criteria, endpoints, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoChange DetectedThe new screenshot shows only minor metadata updates on the TNT trial page, with no changes to the study design, endpoints, eligibility criteria, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoChange DetectedEditorial updates only; there are no changes to inclusion criteria, endpoints, enrollment, or study design. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check32 days agoChange DetectedNo changes detected. The page appears to be unchanged.SummaryDifference0.2%

- Check39 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference3%

- Check47 days agoChange DetectedUpdated version to v3.1.0 and added new contact emails and phone number; removed the old revision indicator v3.0.2.SummaryDifference0.1%

Stay in the know with updates to TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin
Enter your email address, and we'll notify you when there's something new on the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page.